Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 223


VA Cancer Research: A Legacy and A Future.

Bates SE, Kelley MJ.

Semin Oncol. 2019 Aug - Oct;46(4-5):305-307. doi: 10.1053/j.seminoncol.2019.11.001. No abstract available.


A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide.

Leuva H, Sigel K, Zhou M, Wilkerson J, Aggen DH, Park YA, Anderson CB, Hsu TM, Langhoff E, McWilliams G, Drake CG, Simon R, Bates SE, Fojo T.

Semin Oncol. 2019 Aug - Oct;46(4-5):351-361. doi: 10.1053/j.seminoncol.2019.11.004. Epub 2019 Nov 16. Review.


Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain.

Strope JD, Peer CJ, Sissung TM, Hall OM, Huang PA, Harris EM, Gustafson KR, Henrich CJ, Sigano DM, Pauly GT, Schneider JP, Bates SE, Figg WD.

Cancer Biol Ther. 2019 Nov 10:1-8. doi: 10.1080/15384047.2019.1683324. [Epub ahead of print]


Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma.

Dallos MC, Eisenberger AB, Bates SE.

Oncologist. 2019 Oct 1. pii: theoncologist.2019-0264. doi: 10.1634/theoncologist.2019-0264. [Epub ahead of print]


Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.

Pal I, Safari M, Jovanovic M, Bates SE, Deng C.

Curr Hematol Malig Rep. 2019 Aug;14(4):219-227. doi: 10.1007/s11899-019-00530-y. Review.


PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting.

Bates SE.

Oncologist. 2019 May;24(5):571-573. doi: 10.1634/theoncologist.2019-0281. No abstract available.


Publish or Perish v2.

Bates SE.

Oncologist. 2019 Jun;24(6):723-724. doi: 10.1634/theoncologist.2019-0319. Epub 2019 May 7. No abstract available.


Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T.

Semin Oncol. 2019 Feb;46(1):83-99. doi: 10.1053/j.seminoncol.2019.01.002. Epub 2019 Jan 26. Review.


Neoadjuvant Treatment for Pancreatic Cancer.

Raufi AG, Manji GA, Chabot JA, Bates SE.

Semin Oncol. 2019 Feb;46(1):19-27. doi: 10.1053/j.seminoncol.2018.12.002. Epub 2018 Dec 28. Review.


Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models.

McDonald AJ, Curt KM, Patel RP, Kozlowski H, Sackett DL, Robey RW, Gottesman MM, Bates SE.

Exp Cell Res. 2019 Feb 15;375(2):106-112. doi: 10.1016/j.yexcr.2018.12.012. Epub 2018 Dec 21.


Entinostat finds a path: A new study elucidates effects of the histone deacetylase inhibitor on the immune system.

Surolia I, Bates SE.

Cancer. 2018 Dec 15;124(24):4597-4600. doi: 10.1002/cncr.31766. Epub 2018 Nov 13. No abstract available.


Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research.

Chabner BA, Bates SE.

Oncologist. 2018 Dec;23(12):1391-1393. doi: 10.1634/theoncologist.2018-0662. Epub 2018 Oct 23.


Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K.

Cancer. 2019 Feb 1;125(3):406-415. doi: 10.1002/cncr.31816. Epub 2018 Oct 20.


Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.

J Natl Cancer Inst. 2019 May 1;111(5):490-497. doi: 10.1093/jnci/djy133.


A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.

Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

Cancer Chemother Pharmacol. 2018 Sep;82(3):565-570. doi: 10.1007/s00280-018-3631-7. Epub 2018 Jun 27.


Revisiting the role of ABC transporters in multidrug-resistant cancer.

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM.

Nat Rev Cancer. 2018 Jul;18(7):452-464. doi: 10.1038/s41568-018-0005-8. Review.


Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.

Zhang GN, Zhang YK, Wang YJ, Gupta P, Ashby CR Jr, Alqahtani S, Deng T, Bates SE, Kaddoumi A, Wurpel JND, Lei YX, Chen ZS.

Cancer Lett. 2018 Jun 28;424:19-29. doi: 10.1016/j.canlet.2018.02.040. Epub 2018 Mar 5.


Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.


Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.

Clin Cancer Res. 2018 Apr 15;24(8):1944-1953. doi: 10.1158/1078-0432.CCR-17-0443. Epub 2018 Feb 1.


Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y.

J Clin Oncol. 2018 Jun 1;36(16):1594-1602. doi: 10.1200/JCO.2017.76.6915. Epub 2017 Dec 18.

Supplemental Content

Loading ...
Support Center